XLO Xilio Therapeutics, Inc. Insider Trading

Director Shannon James Samuel doubles XLO holdings to 10,000 shares ($43,950 buy); prior trades at same ticker averaged 1374–1390% 30-day returns.

Shannon James Samuel, a director of Xilio Therapeutics, purchased 5,000 shares at $8.79 on 2026-03-26, doubling his post-transaction holdings from 5,000 to 10,000 shares. His two prior open-market purchases at this same ticker (both in June 2025) generated exceptional near-term returns, with 30-day gains of 1374.0% and 1390.6%, and 90-day gains of 1428.3% and 1403.3%. The current stock price of $8.24 is -48.8% from the 52-week high of $16.10, suggesting a material pullback from recent peaks. This purchase follows a consistent pattern: both prior buys at XLO were well-timed at the 90-day mark, indicating the stock rose substantially after his entry points. The company remains unprofitable (net income $-16,287,000.00 in the latest quarter) despite rapid annual revenue growth of +589.9%, positioning this as a pre-profitability biotech stage where insider accumulation warrants close observation of execution progress and clinical milestones.

XLO CEO Rene Russo buys 36,289 shares at $0.68 while stock down 55.4% from 52-week high; company unprofitable.

CEO Rene Russo purchased 36,289 shares at $0.68, increasing his holdings by 14.8% to 281,172 shares total. This purchase occurred at a significant distance below the 52-week high of $20.72, and the stock has declined 24.9% over the preceding 30 days. The company is deeply unprofitable, reporting a net loss of $13,265,000.00 against quarterly revenue of $2,930,000.00, indicating substantial cash burn with minimal revenue generation. The magnitude of the purchase—14.8% incremental stake increase—at a depressed price level relative to recent history warrants examination of whether this reflects conviction or execution of a predetermined plan, especially given the company's negative net income trajectory.

Director Shannon James Samuel bought 70,000 shares at $0.69 (totaling $48,085.00) across 2 transactions

Director Shannon James Samuel made 2 separate purchases totaling 70,000 shares for $48,085.00 at a blended average price of $0.69 on June 16–17, 2025. This represents the director's first recorded position in Xilio Therapeutics. The transaction price of $0.69 is significantly below the current price of $9.25—a material gap—yet the stock has declined 55.4% from its 52-week high and 24.9% over the past 30 days, indicating recent downward momentum. The company is unprofitable (net income $-13.3M in the most recent full fiscal year) with minimal quarterly revenue of $2.9M against a market cap of $479.0M, reflecting a pre-revenue or early-stage biotech profile where director share acquisitions warrant scrutiny for alignment with strategic inflection points or capital deployment decisions.

Gilead Sciences (10% owner) buys 1,759,978 shares of Xilio at $1.04; stake grows to 9,105,451 shares (+24.0%)

Gilead Sciences, already a 10% shareholder, executed an open-market purchase of 1,759,978 shares at $1.04 on 2024-12-18, increasing its holdings from 7,345,473 shares to 9,105,451 shares—a substantial +24.0% expansion of its position in Xilio Therapeutics. The timing appears selective: Xilio is trading 38.7% below its 52-week high of $21.42 and down 8.0% over the past 30 days, yet Gilead's prior buy at this ticker on 2024-04-02 yielded 90-day returns of +1601.9%, demonstrating material past success in timing purchases of Xilio. However, Xilio remains unprofitable with net income of $-14,020,000.00 on quarterly revenue of only $2,263,000.00 and a market cap of $577,169,511.62, so fundamental risk remains elevated. The accumulation of a larger stake by an established 10% owner signals persistence in the investment thesis despite near-term price weakness and ongoing losses.